Merck & Co Inc

NYSE:MRK  
78.27
-0.42 (-0.53%)
4:00:00 PM EDT: $78.24 -0.03 (-0.04%)
Products

FDA Approves Merck’S Keytruda Plus Platinum And Fluoropyrimidine-Based Chemotherapy

Published: 03/23/2021 10:53 GMT
Merck & Co Inc (MRK) - FDA Approves Merck’s Keytruda® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-based Chemotherapy for Treatment of Certain Patients With Locally Advanced Or Metastatic Esophageal Or Gastroesophageal Junction (gej) Carcinoma.